Vertex Pharmaceuticals Inc (VRTX) earnings · P/E 30, rev $3.33B
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
This VRTX earnings page is the cached print — revenue, income, and the latest exhibit — not a live call transcript.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
When the next VRTX 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was up 11.6% from 2026-03-31 to 2026-06-30. An earnings headline that ignores that move is noise.
Not investment advice. Full VRTX research stays on the stock page; the tape stays on the quote page.
Not investment advice.